Cardiac troponin‐I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center

Cardiac involvement is a major cause of mortality in patients with thrombotic thrombocytopenic purpura (TTP). However, diagnosis remains underestimated and delayed, owing to subclinical injuries. Cardiac troponin‐I measurement (cTnI) on admission could improve the early diagnosis of cardiac involvement and have prognostic value.

[1]  M. Hennerici,et al.  What Does Elevated High-Sensitive Troponin I in Stroke Patients Mean: Concomitant Acute Myocardial Infarction or a Marker for High-Risk Patients , 2013, Cerebrovascular Diseases.

[2]  F. Peyvandi,et al.  Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies , 2012, British journal of haematology.

[3]  O. Tutarel,et al.  Therapeutic Plasma Exchange Decreases Levels of Routinely Used Cardiac and Inflammatory Biomarkers , 2012, PloS one.

[4]  J. Holz.  The TITAN trial--assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura. , 2012, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[5]  H. Tsai.  Autoimmune Thrombotic Microangiopathy: Advances in Pathogenesis, Diagnosis, and Management , 2012, Seminars in Thrombosis & Hemostasis.

[6]  P. Coppo,et al.  Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. , 2012, Presse medicale.

[7]  G. Choukroun,et al.  Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center , 2012, Critical care medicine.

[8]  Eric Rondeau,et al.  Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience , 2011, Haematologica.

[9]  J. Cavenagh,et al.  A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. , 2011, Blood.

[10]  B. Jilma,et al.  Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura , 2010, Thrombosis and Haemostasis.

[11]  Eric Rondeau,et al.  Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience , 2010, PloS one.

[12]  W. Aronow,et al.  Cardiovascular Manifestations in Patients With Thrombotic Thrombocytopenic Purpura: A Single‐center Experience , 2010, Clinical cardiology.

[13]  S. Vesely,et al.  Survival and relapse in patients with thrombotic thrombocytopenic purpura. , 2010, Blood.

[14]  J. McEwan,et al.  Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13 , 2009, Journal of thrombosis and haemostasis : JTH.

[15]  P. Coppo,et al.  Thrombotic microangiopathies: towards a pathophysiology-based classification. , 2009, Cardiovascular & hematological disorders drug targets.

[16]  D. Sane,et al.  Myocardial infarction in thrombotic thrombocytopenic purpura: a single‐center experience and literature review , 2008, European journal of haematology.

[17]  G. Fonarow,et al.  Cardiac troponin and outcome in acute heart failure. , 2008, The New England journal of medicine.

[18]  S. Vesely,et al.  Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review , 2007, Transfusion.

[19]  S. Vesely,et al.  Twice‐daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006 , 2007, Transfusion.

[20]  É. Oksenhendler,et al.  Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. , 2007, Blood.

[21]  R. Erbel,et al.  Acute myocardial infarction in thrombotic microangiopathies--clinical characteristics, risk factors and outcome. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  J. George,et al.  Clinical practice. Thrombotic thrombocytopenic purpura. , 2006, The New England journal of medicine.

[23]  J. Grande,et al.  Incidence and prognosis of acute heart failure in the thrombotic microangiopathies. , 2005, The American journal of medicine.

[24]  G Bertazzoni,et al.  Prognostic significance of admission levels of troponin I in patients with acute ischaemic stroke , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[25]  G. Hutchins,et al.  Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. , 2003, Archives of pathology & laboratory medicine.

[26]  P O Collinson,et al.  Multicentre evaluation of the diagnostic value of cardiac troponin T, CK-MB mass, and myoglobin for assessing patients with suspected acute coronary syndromes in routine clinical practice , 2003, Heart.

[27]  A. Antony,et al.  Myocardial infarction/injury is relatively common at presentation of acute thrombotic thrombocytopenic purpura: the Indiana University experience. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[28]  F. Schoen,et al.  Massive myocardial necrosis in thrombotic thrombocytopenic purpura: a case report and review of the literature. , 1999, Archives of pathology & laboratory medicine.

[29]  N. Blanckaert,et al.  Analytical and Clinical Performance of Two Cardiac Troponin I Immunoassays , 1999, Clinical chemistry and laboratory medicine.

[30]  W. Bell,et al.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. , 1991, The New England journal of medicine.

[31]  J. Kelton,et al.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. , 1991, The New England journal of medicine.

[32]  B. Vandenberg,et al.  Cardiac manifestations of thrombotic thrombocytopenic purpura. , 1989 .

[33]  J. George.  Thrombotic Thrombocytopenic Purpura , 1988 .

[34]  W. Bell,et al.  Thrombotic Thrombocytopenic Purpura: Report of 25 Cases and Review of the Literature , 1981, Medicine.

[35]  G. Hutchins,et al.  The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. , 1979, Annals of internal medicine.

[36]  T. N. James,et al.  Pathology of the cardiac conduction system in thrombotic thrombocytopenic purpura. , 1966, Annals of internal medicine.

[37]  P. Siersema,et al.  Cardiac manifestations of thrombotic thrombocytopenic purpura. , 1989, The Netherlands journal of medicine.